1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Immunotherapy Drugs Market by Type, by Therapy Area, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

Immunotherapy Drugs Market by Type, by Therapy Area, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

  • October 2018
  • 207 pages
  • ID: 5731277
  • Format: PDF
  • Prescient & Strategic Intelligence Private Limited


Table of Contents

Immunotherapy Drugs Market by Type (Checkpoint Inhibitors [Brand {Humira, Rituxan/MabThera, Herceptin, Remicade, Enbrel}], Vaccines [Type {Preventive, Therapeutic}, Brand {Prevnar/Prevenar 13, Gardasil, ProQuad, Rotarix}]), by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases), by End User (Hospitals & Clinics, Individuals), by Geography (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa) - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

Immunotherapy drugs market is forecasted to attain a size of $227.6 billion by 2023, with the thriving demand and increase in the development of monoclonal antibodies (mAbs), increasing prevalence of chronic diseases, and growing implementation of target therapy, the market is expected to progress significantly in the coming years.

Based on type, the immunotherapy drugs market has been categorized into checkpoint inhibitors and vaccines. Among these two, the checkpoint inhibitors category generated higher revenue in the historical period, and is expected to generate more than $100.0 billion revenue by 2023. Increasing development of mAbs, and rise in the adoption of chimeric antigen receptor (CAR) T-cell therapy are the major factors contributing to the larger share of this category.

Vaccines are further sub-categorized on the basis of type and brand. The two types of vaccines available in the immunotherapy drugs market are preventive and therapeutic vaccines. Among these, preventive vaccines held a larger share in the market. Among the various brand of vaccines available, Prevnar/Prevenar 13 is one of the bestseller vaccines brands and generated the highest revenue of $5.6 billion in the market, in 2017.

Immunotherapy drugs are majorly used for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. Cancer held the largest share in the immunotherapy drugs market for therapy area, in 2017. This can be ascribed to the increasing prevalence of cancer across the globe.

On the basis of end user, the immunotherapy drugs market has been categorized into hospitals and clinics, and individuals. Of these, hospitals and clinics are expected to demonstrate faster growth, at a CAGR of 14.0% during the forecast period. This can be attributed to the increasing patient base in hospitals and clinics, which leads to high requirement of immunotherapy drugs in this end-user category.

The APAC immunotherapy drugs market is expected to observe the fastest growth, at a CAGR of 14.3% during the forecast period, mainly on account of increasing healthcare expenditure for the improvement of healthcare infrastructure and growing research and development (R&D) activities in the region.

The players in the immunotherapy drugs industry are enhancing their product portfolio through product launches and also have received approvals from government organizations for its application. For instance, in September 2018, Sanofi received approval for Libyato for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, who are not candidates for curative surgery or curative radiation.

Likewise, in September 2018, AstraZeneca plc received the U.S. Food and Drug Administration (USFDA) approval for Lumoxiti (moxetumomab pasudotox-tdfk). AstraZeneca plc developed Lumoxiti together with MedImmune LLC, for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL), who have received at least two prior systemic therapies, including purine nucleoside analog treatment.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, Celgene Corporation, and Pfizer Inc. are other key players present in the immunotherapy drugs market.

The scope of study also includes the epidemiology coverage for cancer, autoimmune and inflammatory diseases, and infectious diseases; pricing and reimbursement scenario for immunotherapy drugs; research and funding initiatives for immunotherapy drugs; and list of immunotherapy drugs in the pipeline of the key market players.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on